Liver Cancer Trial, Recruiting NCT07263217 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT07263217
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with cholangiocarcinoma (a type of cancer affecting the bile ducts in the liver).
  • Your liver is functioning at a good level, classified by doctors as "Child-Pugh Class A" (confirm with trial site).
  • You are planned to receive a specific combination of cancer treatments (gemcitabine, oxaliplatin, lenvatinib, and a type of immunotherapy drug) followed by a surgical procedure to remove part of the liver, with enough healthy liver remaining afterward.
  • You are between 18 and 75 years old, of any gender.
  • You are willing and able to take either spirulina (a natural supplement) or a placebo by mouth for 3 weeks before and 3 weeks after your surgery, as part of the study.
  • You are willing to follow all parts of the study plan and sign a consent form agreeing to take part.
  • You have not had any new sudden illness or significant worsening of symptoms in the 4 weeks before joining the trial.

Who may not be able to join:

  • You have serious ongoing health conditions that are not well controlled, such as heart, lung, kidney, or blood disorders.
  • You have a known allergy to spirulina or any of its ingredients.
  • You have been diagnosed with another type of cancer at the same time.
  • You have previously had surgery to remove part of your liver.
  • You have a severe mental health condition that could affect your ability to follow the study plan or give informed consent.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86 18768161626

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 October 2025
Est. completion
30 September 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change in Alanine Aminotransferase (ALT) Level; Change in Aspartate Aminotransferase (AST) Level; Change in Total Bilirubin (TBIL) Level

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov